The IMPACT study was developed and implemented with the oversight of an expert Steering Committee comprised of a variety of leading AD specialists, including geriatricians, neurologists, epidemiologists, primary care physicians, old-age psychiatrists and advocacy leaders from the United Kingdom, France, Italy, Spain and Germany. The Committee was sponsored by Eisai and Pfizer Inc.
About Eisai
Eisai is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: Integrative Neuroscience including neuroscience, neurology and psychiatric medicine; Integrative Oncology including oncotherapy and supportive-care treatment and Vascular/Immunological Reaction which includes acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis and Crohn's disease. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Globally, Eisai operates in five key regions: its home market of Japan, North America, China, Asia/Oceania/Middle East and Europe and employs more than 11,000 people worldwide.
Pfizer Inc: Working together for a healthier world(TM)
Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.
(1) Impact Study 2009: Global Alzheimer's Awareness Study. Data on
File Eisai, Pfizer Ltd
(2) Alzheimer Europe. Dementia in Europe Yearbook 2008. Alzheimer Europe.
2008.
(3) Mohs, R.C. et al. A 1-year, placebo-controlled preservation of
function survival study of donepezil in AD patients. Neurology. 2001;
57:481-488.
(4) Wimo, A. et al. An Economic Evaluation of Donepezil in Mild to
Moderate Alzheimer's Disease: Results of a 1-year, Double-Blind,
Randomized Trial. Dementia and Geriatric Cognitive Disorders. 2003;
15:44-54.
(5) Feldman, H. et al. Efficacy of Donepezil on Maintenance of
Activities of Daily Living in Patients with Moderate to Severe
Alzheimer's Disease and the Effect on Caregiver Burden. Journal
American Geriatrics Society. 2003; 51:737-744.
(6) Geldmacher, D. et al. Donepezil Is Associated with Delayed Nursing
Home Placement in Patients with Alzheimer's Disease. Journal
American Geriatrics Society. 2003; 51:937-944.
(7) Alzheimer's Association. Diagnosis. Available at
http://alz.org/alzheimers_disease_diagno... and
http://alz.org/alzheimers_disease_life_a...
(8) Alzheimer Europe. Policy watch Europe Unites Against Alzheimer's
disease. Dementia In Europe: The Alzheimer Europe Magazine. December
2008;2: 2-11.
(9) Alzheimer's Association. 2009 Alzheimer's Disease Facts and Figures.
Available at:
http://www.nadsa.org/publications/docume....
Accessed, June 9, 2009.
(10) Wortmann, M. et al. New Estimates of Numbers of People With Dementia
Worldwide. Alzheimer's Disease International Global Perspective.
2008;18: 10-12.
(11) Alzheimer's Association. 10 Signs of Alzheimer's
http://www.alz.org/alzheimers_disease_10...
(12) Alzheimer's Association. Treatments Available at
http://alz.org/alzheimers_disease_treatm... and
http://www.alz.org/alzheimers_disease_st...
Andrew Day, Eisai, +44-7973-411-419, Andrew_day@eisai.net; or Louise Clark, Pfizer, +44-845-300-8033, pressofficeUK@pfizer.com; or Vanessa Leon, Chamberlain, +44-20-7611-8091, Vleon@chamberlainpr.com